---
layout: post
title: "Secura Bio, Inc.; Withdrawal of Approval of Relapsed or Refractory Follicular Lymphoma Indication for COPIKTRA"
date: 2026-02-05 18:58:48 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-07931
original_published: 2022-04-13 00:00:00 +0000
significance: 8.00
---

# Secura Bio, Inc.; Withdrawal of Approval of Relapsed or Refractory Follicular Lymphoma Indication for COPIKTRA

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** April 13, 2022 00:00 UTC
**Document Number:** 2022-07931

## Summary

The Food and Drug Administration (FDA) is announcing that it is withdrawing approval of the relapsed or refractory follicular lymphoma indication for COPIKTRA (duvelisib) Capsules, approved under new drug application 211155, held by Secura Bio, Inc., 1995 Village Center Circle, Suite 128, Las Vegas, NV 89134. Secura Bio, Inc. voluntarily requested that the Agency withdraw approval of this indication and has waived its opportunity for a hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/04/13/2022-07931/secura-bio-inc-withdrawal-of-approval-of-relapsed-or-refractory-follicular-lymphoma-indication-for)
- API: https://www.federalregister.gov/api/v1/documents/2022-07931

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
